Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$0.63 - $1.44 $1,512 - $3,456
2,400 Added 4.13%
60,500 $45,000
Q1 2022

May 16, 2022

BUY
$1.03 - $1.77 $1,236 - $2,124
1,200 Added 2.11%
58,100 $86,000
Q4 2021

Feb 14, 2022

BUY
$1.38 - $2.17 $78,522 - $123,473
56,900 New
56,900 $84,000

Others Institutions Holding IKT

About Inhibikase Therapeutics, Inc.


  • Ticker IKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,227,100
  • Market Cap $83.8M
  • Description
  • Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...
More about IKT
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.